Zuberitamab for first episode of nephrotic syndrome in children
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called zuberitamab for children who have just had their first episode of nephrotic syndrome and have responded well to steroids. The goal is to see if this medicine can help keep the disease from coming back, with fewer side effects than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have just been diagnosed with steroid-sensitive nephrotic syndrome (a kidney condition that responds to steroids) and have already gone into remission after taking steroids.
- You must have good kidney function at the start of the study.
- You must have enough CD19+ cells (a type of immune cell) in your blood.
- You must not have used any immunosuppressant drugs (other than steroids) in the past 3 months.
- You must not have other causes of kidney disease, such as lupus or IgA nephropathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children with nephrotic syndrome (a kidney condition causing swelling) who are being treated for the first time with rituximab. It aims to see how well the medication works long-term.
This study tracks children with nephrotic syndrome whose kidney disease does not respond to usual treatments. It aims to collect information and samples to better understand resistant forms of the condition.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests a new medicine called zuberitamab for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The treatment aims to reduce protein loss and improve kidney function.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.